
Editorial review
Educational content is reviewed for source quality, clinical boundaries, and readability. It is not medical advice; confirm care decisions with a licensed clinician.
What Number Needed to Treat (NNT) Means in Ketamine Research
Number needed to treat (NNT) is a statistic from a clinical trial that tells you how many patients would need to receive a treatment, such as a ketamine infusion or esketamine (Spravato) nasal spray, for one additional patient to reach a defined outcome, compared with a control group receiving placebo or a different treatment. It is reported alongside, not instead of, measures like average symptom change, and it comes directly from a trial's own response rates rather than a formula unique to ketamine research.
Quick Answer
NNT equals 1 divided by the absolute risk reduction between a treatment arm and a control arm in a clinical trial. Published ketamine and esketamine depression trials have generally reported single-digit NNT values, often clustering in the rough range of 3 to 8, for short-term treatment response versus placebo or an active comparator. The exact figure depends on how "response" was defined, the timepoint measured, and which comparator was used, so NNT values from different studies are not directly interchangeable.
How NNT Is Calculated
NNT is the inverse of the absolute risk reduction (ARR) between two groups in a trial: NNT = 1 ÷ (response rate in the treatment group minus response rate in the control group). A smaller NNT means fewer patients need treatment for one extra person to benefit relative to the comparator used in that specific study.
As a generic example, if 50% of patients responded to a treatment and 20% responded to placebo, the ARR is 0.30 (50% minus 20%). Dividing 1 by 0.30 gives an NNT of about 3.3, usually rounded up to 4. That means roughly 1 additional patient would respond for every 4 patients treated, compared with placebo, in that trial.
Compare evidence and options
Compare ketamine with other treatment paths using neutral explainers.
Compare optionsNNT in Published Ketamine and Esketamine Depression Trials
Esketamine (Spravato) is the only ketamine-related treatment with FDA approval, granted in 2019, for treatment-resistant depression in adults, based on randomized trials comparing it with an oral antidepressant plus placebo nasal spray. Generic (racemic) ketamine, delivered by IV, IM, or other routes, remains an off-label use for depression, usually studied in smaller trials that compare it with a saline infusion or an active control designed to mimic ketamine's side effects.
Across both types of trials, published analyses have generally reported single-digit NNT values, often in the rough range of 3 to 8, for outcomes like a 50% or greater symptom reduction measured by scales such as the Clinical Global Impression Scale or the Montgomery-Asberg Depression Rating Scale, at timepoints from 24 hours to 4 weeks after dosing. These figures reflect the specific populations, doses, and comparators used in each study, not a single fixed NNT for ketamine as a treatment category. For more on how researchers define and measure outcomes in this literature, see how to read ketamine depression research studies.
Key Takeaway
NNT measures a treatment's effect relative to the specific comparator used in a trial, not against doing nothing or against a different route of ketamine administration. A trial reporting an NNT of 4 for esketamine versus placebo cannot be directly compared to a different trial reporting an NNT of 6 for IV ketamine versus saline, because the populations, doses, and definitions of response differ.
Why NNT Has Limits in Ketamine Research
Ketamine and esketamine produce dissociative effects that patients and clinicians can often notice within minutes of dosing. Because a placebo typically does not cause these sensations, some trial participants and raters may correctly guess who received the active drug, a problem researchers call functional unblinding. If unblinding inflates perceived improvement in the treatment group or shifts ratings in the placebo group, the reported ARR, and therefore the NNT, can move in ways that do not reflect the drug's true effect. Published NNT figures for ketamine and esketamine are best read alongside a trial's blinding methods, not in isolation.
NNT also says nothing about durability or safety. A trial can report a favorable short-term NNT for response while patients also experience side effects or discontinue treatment at meaningful rates, and a single-digit NNT at 24 hours does not guarantee the same benefit at 4 weeks or 3 months. This article is educational and does not replace advice from a licensed clinician familiar with your diagnosis, medical history, and treatment options.
How to Use NNT When Reading a Ketamine Trial
- Check which outcome the NNT applies to: response, remission, or relapse prevention
- Note the timepoint: 24-hour, day-28, and week-4 outcomes are not interchangeable
- Identify the comparator: placebo, an active antidepressant, or a saline infusion
- Look for the confidence interval around the NNT, not just the single number
- Avoid comparing NNT values across trials that use different response definitions
Compare Ketamine Delivery Methods
Reading trial statistics like NNT is one part of comparing ketamine and esketamine options. See how routes, evidence quality, and supervision requirements differ.
Frequently Asked Questions
Generally, yes: a lower NNT means fewer patients need to be treated for one additional person to benefit relative to the comparator in that trial. But NNT should be weighed alongside the comparator used, the outcome definition, confidence intervals, and safety data, not treated as a standalone score.
There is no single accepted cutoff. Researchers and clinicians generally consider single-digit NNT values, roughly under 10, for short-term antidepressant response to reflect an effect worth weighing against risks and burdens, but what counts as meaningful depends on the condition, the comparator, and the patient's other options.
The concept is the same, but the numbers are not interchangeable. IV ketamine trials and esketamine trials use different doses, routes, control conditions, and patient populations, so each trial's NNT reflects only that specific comparison.
NNT is not always reported directly in a trial's primary publication. You may need to calculate it from the published response rates in the treatment and control arms, or look for a secondary meta-analysis or systematic review that reports it, searchable through PubMed.
Share
Related Reading
Contact Ketamine Resource
Send corrections, partnership questions, or advertising inquiries.


